Drug substance : RGIC®100 (GMP TLR3 ligand)

Riboxxim RGC 2.png

Fig. 1. Interaction of RGIC100 with the TLR3 homodimer. Structural model of one molecule of RGIC100 ligating 2 TLR3 monomers.

Biological activity

Ligand of TLR3 and RLR (Naumann et al., Clin. Dev. Immunol., 2013)


  • RGIC100 generates a Th1 immune response with a particular activation of CD8+ positive T cells and NK cells.
  • RGIC100 strongly activates dendritic cells and monocytes (Naumann et al., Clin. Dev. Immunol., 2013).
  • RGIC100 has a very well defined chemical structure, length and molecular weight, and a good solubility (Naumann et al., Clin. Dev. Immunol., 2013).
  • RGIC100 is stable in body fluids up to seven days (Naumann et al., Clin. Dev. Immunol., 2013).
  • RGIC100 is less toxic than poly(I:C) and has a much higher LD50 than poly(I:C).

Development stage

  • RGIC100 has completed all pre-clinical development stages including GMP manufacturing.
  • GMP TLR3 ligand RGIC100 is available for pharmaceutical companies or public institutions performing Phase I to III clinical studies in cancer or virus diseases (immunotherapy, immunoncology).
Cookies faciliate the providing of our online services. By using our online services, you agree to our use of cookies.